[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
April 20, 2011

Experts Debate Utility of PSA Velocity as a Criterion for Prostate Biopsy

JAMA. 2011;305(15):1522. doi:10.1001/jama.2011.492

The authors of a new study argue that an add-on to improve traditional prostate-specific antigen (PSA) screening for prostate cancer provides minimal benefit in identifying those cancers that are truly life threatening and should not be recommended in practice guidelines. But other experts reject this controversial opinion.

PSA screening remains a less-than-ideal method for detecting deadly prostate cancer, and researchers have tried to improve its specificity by adding other variables, such as race or family history, or different measures of PSA level, such as free PSA and PSA isoforms.

First Page Preview View Large
First page PDF preview
First page PDF preview